Pharmafile Logo

patient interaction

- PMLiVE

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood

- PMLiVE

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.

Cuttsy + Cuttsy

- PMLiVE

It’s time to stop calling adverse events ‘manageable’

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.

Cuttsy + Cuttsy

- PMLiVE

Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA

Globally, around 150 to 200 out of every million people have myasthenia gravis

- PMLiVE

EMA celebrates diversity and inclusion in science and healthcare

The EU body underlines its commitment to diverse perspectives in medicines regulation

- PMLiVE

Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer

Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer

- PMLiVE

EMA’s PRIME scheme launches three major new features

The scheme supports the development of treatments targeting unmet medical needs in the EU

- PMLiVE

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

Cuttsy + Cuttsy

- PMLiVE

New Cuttsy+Cuttsy research shows why site support matters more than ever

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Cuttsy + Cuttsy

- PMLiVE

How can pharma build genuine partnerships with patient communities?

Patient engagement is not optional in pharma – it’s integral. Meaningful partnerships with patients, caregivers and advocates must shape every stage of healthcare and medicines development, driving better outcomes, equity...

Amiculum

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links